title: Hyperparathyroidism associated with a chronic hypothyroid state.
abstract: Reports of the coexistence of hyperparathyroidism and thyroid disease have raised the issue of a possible etiologic relationship. The present study tests the hypothesis that chronic elevation of thyroid-stimulating hormone (TSH) is related to the development of hyperparathyroidism. Four groups of 60 female rats were treated as follows: group 1, control; group 2, propylthiouracil (PTU) 0.0025%; group 3, PTU 0.0025% plus thyroxine, 5 microg two times per week; and group 4, only thyroxine. The animals' serum calcium, phosphorus, TSH, thyroxine, and parathyroid hormone (PTH) levels were evaluated at 0, 6, 12, and 18 months. Significant elevation of TSH was sustained throughout the 18 months in groups 2 and 3. The PTH levels were also significantly elevated in both group 2 and group 3 animals (P = 0.02). The histopathologic features of the parathyroids were evaluated at 18 months. In the group 2 (PTU only) animals, which had profound hypothyroid, 44% developed parathyroid adenomas. In the group 3 (PTU plus thyroxine) animals, who had mildly elevated TSH levels, 53% developed parathyroid adenomas. These findings are consistent with the hypothesis that prolonged TSH stimulation may lead to hyperparathyroidism in the rat model.
authors.affiliation: Department of Otolaryngology, Loyola University Medical Center, Maywood, Illinois 60153, USA.
authors.forename: R
authors.initials: R
authors.lastname: Paloyan Walker
authors.forename: E
authors.initials: E
authors.lastname: Kazuko
authors.forename: C
authors.initials: C
authors.lastname: Gopalsami
authors.forename: J
authors.initials: J
authors.lastname: Bassali
authors.forename: A M
authors.initials: AM
authors.lastname: Lawrence
authors.forename: E
authors.initials: E
authors.lastname: Paloyan
mesh_terms: D000236:Adenoma / Q000209:etiology; D000818:Animals; D013956:Antithyroid Agents / Q000008:administration & dosage / Q000494:pharmacology; D002118:Calcium / Q000097:blood; D002908:Chronic Disease; D004195:Disease Models, Animal; D005260:Female; D006961:Hyperparathyroidism / Q000209:etiology* / Q000473:pathology; D006965:Hyperplasia; D007037:Hypothyroidism / Q000097:blood / Q000150:complications*; D010280:Parathyroid Glands / Q000473:pathology; D010281:Parathyroid Hormone / Q000097:blood; D010282:Parathyroid Neoplasms / Q000209:etiology; D010758:Phosphorus / Q000097:blood; D011441:Propylthiouracil / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D015996:Survival Rate; D013961:Thyroid Gland / Q000473:pathology; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology
chemical_list: D013956:Antithyroid Agents; D010281:Parathyroid Hormone; D010758:Phosphorus; D011441:Propylthiouracil; D013972:Thyrotropin; D013974:Thyroxine; D002118:Calcium